US 20190142851A1 ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0142851 A1 CHADEAYNE (43 ) Pub. Date : May 16 , 2019 ( 54 ) COMPOSITIONS COMPRISING A 2017 , provisional application No. 62/ 587, 410 , filed PSILOCYBIN DERIVATIVE AND A on Nov. 16 , 2017 , provisional application No . 62 /587 , CANNABINOID 395 , filed on Nov . 16 , 2017 . (71 ) Applicant: CaaMTech , LLC , Issaquah , WA (US ) Publication Classification (51 ) Int . Ci. ( 72 ) Inventor: Andrew R . CHADEAYNE , Issaquah , A61K 31/ 675 ( 2006 .01 ) WA (US ) A61K 31 / 4045 (2006 . 01 ) A61K 31/ 4406 ( 2006 .01 ) (21 ) Appl. No. : 16 / 192, 736 A61K 31/ 05 (2006 . 01) A61K 31 / 192 (2006 .01 ) ( 22 ) Filed : Nov . 15 , 2018 A61K 31 /353 ( 2006 . 01) (52 ) U . S . CI. Related U . S . Application Data CPC .. A61K 31/ 675 ( 2013 .01 ) ; A61K 31/ 4045 (60 ) Provisional application No . 62/ 613 , 360 , filed on Jan . (2013 . 01 ) ; A61K 31/ 353 (2013 .01 ) ; ACIK 3 , 2018 , provisional application No. 62 /609 , 115 , filed 31/ 05 (2013 . 01 ) ; A61K 31/ 192 (2013 . 01 ) ; on Dec . 21 , 2017 , provisional application No . 62/ 598 , A61K 31 /4406 ( 2013 . 01 ) 767, filed on Dec . 14 , 2017 , provisional application No . 62 /595 ,336 , filed on Dec . 6 , 2017 , provisional ( 57 ) ABSTRACT application No . 62 / 595 , 321 , filed on Dec . 6 , 2017 , This disclosure pertains to new compositions and methods provisional application No . 62 /593 ,021 , filed on Nov . comprising a psilocybin derivative . In one embodiment, the 30 , 2017 , provisional application No . 62 / 592, 320 , compositions disclosed herein are used for a method of filed on Nov . 29 , 2017 , provisional application No . regulating a neurotransmitter receptor , e . g . , a serotonin 62/ 592 , 307 , filed on Nov . 29, 2017 , provisional appli receptor . In one embodiment, the compositions disclosed cation No . 62 /587 ,431 , filed on Nov. 16 , 2017 , pro herein comprise purified compounds, e . g ., a purified psilo visional application No. 62/ 587 ,419 , filed on Nov. 16 , cybin derivative , a purified cannabinoid , or purified terpene . US 2019 /0142851 A1 May 16 , 2019 COMPOSITIONS COMPRISING A Psilocin ( 4 -hydroxy - N , N - dimethyltryptamine ) is considered PSILOCYBIN DERIVATIVE AND A to be the second most abundant compound . Many within the CANNABINOID scientific community consider psilocin to be the only active ingredient in “ magic mushrooms, " reasoning that psilocybin CROSS REFERENCE TO OTHER RELATED serves only as a prodrug and does not have activity itself . No APPLICATIONS conclusive studies have been conducted to support or under mine this theory . [ 0001 ] This application claims benefit under 35 U . S . C . [0007 ] Formulated and administered correctly , psilocin 119 ( e ) to U . S . Provisional Application Nos. 62 /613 , 360 filed and psilocybin provide fast -acting and long - lasting changes Jan . 3 , 2018 ; 62/ 609 ,115 filed Dec . 21, 2017 ; 62 /598 ,767 to a person ' s mood . These effects can be accomplished with filed Dec . 14 , 2017 ; 62 / 595 , 336 filed Dec . 6 , 2017 ; 62/ 595 , only minor side effects , low potential for addiction , low 321 filed Dec . 6 , 2017 ; 62 / 593 ,021 filed Nov . 30 , 2017 ; potential for abuse , and low risk of toxicity . 62 /592 , 320 filed Nov . 29 , 2017 ; 62 /592 , 307 filed Nov. 29 , [0008 ] Currently , the state of the art for psilocybin tech 2017 ; 62 /587 , 431 filed Nov . 16 , 2017 ; 62 / 587 ,419 filed Nov . nology is not advanced . Despite a handful of studies utiliz 16 , 2017 ; 62/ 587 ,410 filed Nov . 16 , 2017 ; and 62 /587 ,395 ing purified psilocybin as a single active pharmaceutical filed Nov. 16 , 2017 , all of which are hereby incorporated by ingredient , virtually no work has been done formulating reference in their entireties . psilocybin into drug products for treating mental disorders . TECHNICAL FIELD Aside from a few studies on purified psilocybin , no efforts have been made to modulate its properties with formulating [0002 ] This disclosure relates to psilocybin technology, agents or other ingredients . No efforts have been made to which at the time of this disclosure is primarily concerned formulate particular combinations or doses of psilocybin with mycology, mushroom cultivation , crude mushroom derivatives or combinations with other active molecules . No extracts , natural mushroom preparations, fruitbody extracts , efforts have been made to formulate psilocybin into com mycelium preparations, and ( in a few cases ) the isolated positions capable of modifying activity at one or more compound psilocybin . neurotransmitter receptors . 100091. The psilocybin arts focus primarily on cultivating BACKGROUND and consuming mushrooms. Unfortunately, collecting and [ 0003 ] Many people worldwide are afflicted with psycho ingesting mushrooms can be dangerous because of difficul logical or mood disorders , such as depression , anxiety , ties distinguishing the desired mushroom species from simi compulsion , and post - traumatic stress disorders. Many of lar looking species . For example , mushrooms of the genus these conditions are believed to involve a person ' s serotonin Psilocybe are easily confused with toxic lookalikes. Mis system — including interactions between ( A ) the neurotrans taken identification of Psilocybe mushrooms leads to cases mitter serotonin (often abbreviated 5 -HT ) and ( B ) several of serious illness and death every year. different subtypes of serotonin neurotransmitter receptors [0010 ] Even when “magic mushrooms” are properly iden found in the human body. tified , those mushrooms vary greatly in terms of the con [0004 ] A variety of compositions are known to modulate centration of psilocybin , psilocin , and other (often over activity at the serotonin receptors . A number of pharmaceu looked ) active ingredients . Accordingly, administering a ticals ( antidepressants , serotonin reuptake inhibitors , selec specific compound or a particular dose using mushrooms is tive serotonin reuptake inhibitors , etc . ) have become avail not possible because of the variability in the chemical able . In 2014 , the Better Communication Company composition of mushrooms . projected the global market for drugs treating mental disor [0011 ] Additionally, even when “ magic mushrooms” are ders to be about $ 77 . 1 billion by 2018 and register a properly identified , they are prone to contamination . Con five - year compound annual growth rate of 2 . 3 % from 2013 tamination can result in problems, such as unwanted side to 2018 . Almost all these pharmaceuticals target neurotrans effects like “ wood lover paralysis . " mitters , e . g . , serotonergic receptors , adrenergic receptors , [0012 ] Very little work has been done with psilocybin dopaminergic receptors, etc ., and in different ways . All 10 of pharmacology because of the arts ' general understanding not the leading pharmaceutical products for treating mood dis to pursue psilocybin formulations . To the contrary , the orders ( such as depression , obsessive - compulsive disorder, current state of the art focuses almost exclusively on " magic and /or anxiety disorders ) target serotonin pathways. mushrooms. ” The highest authorities on the subject in the [ 0005 ] However, despite their unquestionable popularity United States still maintain that psilocybin has " no benefi and commercial success , the users of these pharmaceutical cial purpose ” and carries a " high potential for abuse .” products are unsatisfied with their long onset times , severe [0013 ] Until recently , very little work had been done in side -effects , and poor efficacy. In many cases , these drugs developing therapeutic methods comprising psilocybin . are harmful to the user. For example , many people taking Recent efforts have shown that taking pure isolated psilo prescription drugs targeting serotonin report feeling suicidal cybin shows promise for treating several psychological thoughts , sexual dysfunction , fatigue , elevated blood pres conditions , such as post -traumatic stress , anxiety , addiction , sure , blurred vision , abnormal heart rate , nausea , and weight depression , and compulsion . On Nov. 6 , 2017 , Newsweek gain . Magazine explained the state of the art as follows: “ Magic [ 0006 ] So - called " magic mushrooms” are taken recre mushrooms ( active psilocybin ' ) were used as an experimen ationally by millions of people in the United States . Psilo talmedical treatment in the 1960s, and some researchers are cybin ( also known as 4 - phosphoryloxy - N , N - dimethyl again looking to them for healing . For example , in a pilot tryptamine or [ 3 - ( 2 - trimethylaminoethyl ) - 1H -indol - 4 - yl] study in 2011 , mushrooms appeared to have a positive effect dihydrogen phosphate ) is considered to be the most abun on cancer patients with anxiety . In 2016 , a study demon dant psychoactive compound within a “ magic mushroom .” strated their use in treating depression .” US 2019 /0142851 A1 May 16 , 2019 [0014 ] Because psilocybin research is a relatively small ment, the methods disclosed herein comprise administering area , virtually no work has been done formulating psilocy a first dosage formulation comprising a first purified can bin or studying the pharmacology of psilocybin , its deriva nabinoid . In one embodiment, the methods disclosed herein tives , and new formulations comprising them . Properly comprise administering a first dosage formulation compris studying , formulating , and dosing psilocybin and its deriva ing a first purified terpene